Clinical Trials in Alzheimer’s Disease (CTAD) conference

Presentations related to BAN2401 were given at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference, held December 4-7 in San Diego, USA.

BioArctic’s partner Eisai presented data from the ongoing BAN2401 Phase 2b open label extension study in early Alzheimer’s disease as well as the study design and current status of the ongoing Phase 3 study, Clarity AD.

Professor Lars Lannfelt, Uppsala University and BioArctic, presented binding profiles of BAN2401 and aducanumab to different forms of amyloid-beta.